|
|
 |
Resources for ResearchersPreclinical Product Development- NIAID supports contract resources that provide preclinical in vitro screening of candidate drugs for hepatitis B and hepatitis C. These systems have been further standardized by the Government contractors and are available to academic and pharmaceutical company sponsors free of charge.
- The HBV model (Korba & Milman, Antiviral Res. 1991 Mar-Apr; 15(3):217-28) with human hepatoma cells transfected with HBV, is under contract to Georgetown University. One HCV model is an enhanced 1b replicon with stable luciferase reporter expression is supported by a contract to the Southern Research Institute (SRI) (R. Bartenschlager’s lab, Science. 1999 Jul 2;285(5424):26-30). And a second HCV culture model is a 1a replicon with similar readout (C. Rice’s lab, Science. 2000 Dec 8;290(5498):1870-1).
- A third HCV in vitro screen uses a SEAP reporter replicon (S. Lemon’s lab, Virology. 2002 Dec 20;304(2):197-210.).
- For several years, NIAID has provided two preclinical animal models for evaluation of therapeutic candidates for hepatitis B. Our Utah State University contract has refined the HBV transgenic mouse model developed initially at Scripps Research Institute (Guidotti, Chirsari et al. J Virol. 1995 Oct;69(10):6158-69) for use by academic and pharmaceutical sponsors. Also available is the woodchuck animal model contract at Cornell University (Gerin, Tennant, et al. Prog Clin Biol Res. 1983;143:23-8.). Woodchucks—infected with a well-characterized pool of woodchuck hepatitis virus—are the closest infection model to humans for preclinical testing of therapies for hepatitis B.
- Recently NIAID added a contract focused on preclinical evaluation of therapies and vaccines for HCV. It provides access to the SCID-Alb-uPA chimera mouse model engrafted with human livers housed at KMT Hepatech in Edmonton, Alberta, Canada (Mercer, Tyrrell, Kneteman et al. Nat Med. 2001 Aug;7(8):927-33).
back to top |
|
|
|